Qianjiang Yongan Pharmaceutical Co., Ltd.

Symbol: 002365.SZ

SHZ

8.24

CNY

Market price today

  • 1754.3477

    P/E Ratio

  • 28.8214

    PEG Ratio

  • 2.43B

    MRK Cap

  • 0.01%

    DIV Yield

Qianjiang Yongan Pharmaceutical Co., Ltd. (002365-SZ) Stock Price & Analysis

Shares Outstanding

294.68M

Gross Profit Margin

0.25%

Operating Profit Margin

-0.05%

Net Profit Margin

0.00%

Return on Assets

0.00%

Return on Equity

0.00%

Return on Capital Employed

-0.02%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Ms. Ding Hongli
Full-time employees:887
City:Qianjiang
Address:No. 2 Guangze Avenue
IPO:2010-03-05
CIK:

Qianjiang Yongan Pharmaceutical Co., Ltd. manufactures and sells taurine in China. The company was founded in 2001 and is based in Qianjiang, China.

General Outlook

In simple terms, Qianjiang Yongan Pharmaceutical Co., Ltd. has 294.683 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.248% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.045%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.002%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.001% return, is a testament to Qianjiang Yongan Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Qianjiang Yongan Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.001%. Furthermore, the proficiency of Qianjiang Yongan Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable -0.018% return on capital employed.

Stock Prices

Qianjiang Yongan Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $7.56, while its low point bottomed out at $7.4. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Qianjiang Yongan Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 002365.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 539.19% gauges short-term asset coverage for liabilities. The quick ratio (496.36%) assesses immediate liquidity, while the cash ratio (111.26%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio539.19%
Quick Ratio496.36%
Cash Ratio111.26%

Profitability Ratios

002365.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 2.77% underscores its earnings before tax deductions. The effective tax rate stands at 162.48%, revealing its tax efficiency. The net income per EBT, 5.85%, and the EBT per EBIT, -61.30%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -4.51%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin2.77%
Effective Tax Rate162.48%
Net Income per EBT5.85%
EBT per EBIT-61.30%
EBIT per Revenue-4.51%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 5.39, it details the span from stock purchase to revenue. The 5 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 461.27% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding496
Days of Inventory Outstanding44
Operating Cycle123.15
Days of Payables Outstanding76
Cash Conversion Cycle48
Receivables Turnover4.61
Payables Turnover4.83
Inventory Turnover8.29
Fixed Asset Turnover0.89
Asset Turnover0.37

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.59, and free cash flow per share, 0.19, depict cash generation on a per-share basis. The cash per share value, 3.07, showcases liquidity position. A payout ratio of 32.23 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.20, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.59
Free Cash Flow per Share0.19
Cash per Share3.07
Payout Ratio32.23
Operating Cash Flow Sales Ratio0.20
Free Cash Flow to Operating Cash Flow Ratio0.32
Cash Flow Coverage Ratio15.84
Short Term Coverage Ratio15.84
Capital Expenditure Coverage Ratio1.47
Dividend Paid and Capex Coverage Ratio1.07
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.47%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.01, we discern the balance between debt and equity financing. An interest coverage of -133.61 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio0.47%
Debt Equity Ratio0.01
Total Debt to Capitalization0.55%
Interest Coverage-133.61
Cash Flow to Debt Ratio15.84
Company Equity Multiplier1.15

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 3.27, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.04, reflects the portion of profit attributed to each share. The book value per share, 6.73, represents the net asset value distributed per share, while the tangible book value per share, 6.70, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share3.27
Net Income Per Share-0.04
Book Value Per Share6.73
Tangible Book Value Per Share6.70
Shareholders Equity Per Share6.73
Interest Debt Per Share0.16
Capex Per Share-0.41

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -34.16%, indicates top-line expansion, while the gross profit growth, -52.40%, reveals profitability trends. EBIT growth, -84.07%, and operating income growth, -84.07%, offer insights into operational profitability progression. The net income growth, -108.77%, showcases bottom-line expansion, and the EPS growth, -108.71%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-34.16%
Gross Profit Growth-52.40%
EBIT Growth-84.07%
Operating Income Growth-84.07%
Net Income Growth-108.77%
EPS Growth-108.71%
EPS Diluted Growth-108.71%
Weighted Average Shares Growth0.12%
Dividends per Share Growth2182.38%
Operating Cash Flow Growth-36.93%
Free Cash Flow Growth-48.15%
10-Year Revenue Growth per Share79.75%
5-Year Revenue Growth per Share-5.90%
3-Year Revenue Growth per Share-19.64%
10-Year Operating CF Growth per Share274.52%
5-Year Operating CF Growth per Share-23.57%
3-Year Operating CF Growth per Share15.71%
10-Year Net Income Growth per Share-152.23%
5-Year Net Income Growth per Share-106.77%
3-Year Net Income Growth per Share-111.42%
10-Year Shareholders Equity Growth per Share79.29%
5-Year Shareholders Equity Growth per Share23.39%
3-Year Shareholders Equity Growth per Share10.62%
10-Year Dividend per Share Growth per Share-11.34%
3-Year Dividend per Share Growth per Share-22.98%
Receivables Growth-12.19%
Inventory Growth-53.28%
Asset Growth-3.18%
Book Value per Share Growth-1.78%
Debt Growth18.22%
R&D Expense Growth-7.55%
SGA Expenses Growth-22.11%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 2,670,905,919, captures the company's total value, considering both debt and equity. Income quality, -19.84, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.09, gauges operational efficiency, while the research and development to revenue, 3.88%, highlights investment in innovation. The ratio of intangibles to total assets, 3.53%, indicates the value of non-physical assets, and capex to operating cash flow, -49.43%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value2,670,905,919
Income Quality-19.84
Sales General and Administrative to Revenue0.09
Research and Development to Revenue3.88%
Intangibles to Total Assets3.53%
Capex to Operating Cash Flow-49.43%
Capex to Revenue-12.54%
Capex to Depreciation-89.32%
Graham Number2.52
Return on Tangible Assets-0.54%
Graham Net Net2.83
Working Capital956,340,661
Tangible Asset Value1,973,880,585
Net Current Asset Value923,249,417
Average Receivables190,735,928
Average Payables145,760,854.5
Average Inventory109,746,981
Days Sales Outstanding68
Days Payables Outstanding64
Days of Inventory On Hand35
ROIC-10.94%
ROE-0.01%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.21, and the price to book ratio, 1.21, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.84, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 43.69, and price to operating cash flows, 13.91, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.21
Price to Book Ratio1.21
Price to Sales Ratio2.84
Price Cash Flow Ratio13.91
Price Earnings to Growth Ratio28.82
Enterprise Value Multiple125.09
Price Fair Value1.21
Price to Operating Cash Flow Ratio13.91
Price to Free Cash Flows Ratio43.69
Price to Tangible Book Ratio1.49
Enterprise Value to Sales2.77
Enterprise Value Over EBITDA16.75
EV to Operating Cash Flow10.93
Earnings Yield-0.42%
Free Cash Flow Yield4.19%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 1754.348 in 2024.

What is the ticker symbol of Qianjiang Yongan Pharmaceutical Co., Ltd. stock?

The ticker symbol of Qianjiang Yongan Pharmaceutical Co., Ltd. stock is 002365.SZ.

What is company IPO date?

IPO date of Qianjiang Yongan Pharmaceutical Co., Ltd. is 2010-03-05.

What is company current share price?

Current share price is 8.240 CNY.

What is stock market cap today?

The market cap of stock today is 2428187920.000.

What is PEG ratio in 2024?

The current 28.821 is 28.821 in 2024.

What is the number of employees in 2024?

In 2024 the company has 887.